Introduction Human beings are entitled to good health as a basic necessity across the globe. Consequently, medical services should be provided to public members irrespective of their socio-cultural and economic backgrounds (Dusetzina et al., 2019). However, a case study entitled “The Ethics of Global Drug Pricing” indicates how developed countries with productive pharmaceutical companies capitalize on profitability over ethics when delivering life-saving prescriptions to patients (Hurst, 2017). From a moral perspective, it is immoral to commercialize vital medication products required by individuals for survival. Treatment of chronic illnesses such as cancer, tuberculosis, and diabetes requires accuracy and time effectiveness for positive health outcomes (Dusetzina et al., 2019). The approach would be useful as all patients would access fundamental medical items. Government agencies and institutions in both developed and developing nations should be objective in integrating ethics to sustain global drug pricing standards. Recognize Decision Requirement Several ethical issues have been presented regarding drug pricing in the mentioned case. It is important to highlight the importance of the business context of pharmaceutical companies as evidenced in the United States (U.S.), United Kingdom (U.K.), and the European Union (E.U.). These countries have leading medical institutions that produce drugs for healthcare agencies across the globe (Dusetzina et al., 2019). The case highlights that some of the companies increase prices of life-saving medicines to maximize demand for profitability. This business approach would justify why drug prices hike during high-demand periods (Dusetzina et al., 2019). For instance, a rise in manufacturing cost would imply higher prices than before to cater to the production needs. However, many patients fail to access vital drugs due to high and unaffordable prices. The ethical issue in drug pricing entails unreasonable profitability, which exploits individuals from low-income backgrounds. Patients suffering from chronic illnesses in developing nations succumb to treatable illnesses such as diabetes, tuberculosis, and cancer (Dusetzina et al., 2019). As a result, the element of high returns on capital investments in global drug pricing should be morally rectified with moral values that protect all public members seeking healthcare services. Diagnosis and Analysis of Causes Monopoly pricing constitutes justifiable reasons regarding expensive medication within the U.S. The country has leading pharmaceutical companies that are unmatched in production capabilities and scope of operation (Dusetzina et al., 2019). The experts employed in these entities depict high academic and professional standards to ensure the quality production of medical products. Monopoly pricing arises when companies use high monetary value to sell the product to patients. The case study provided notes that the companies can significantly increase pharmaceuticals prices (Wouters & Kanavos, 2017). The U.S. allows these entities to determine price tags based on market affordability and production costs. In essence, the model exploits patients who find vital medications unaffordable (Dusetzina et al.